<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436668</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1137-CA</org_study_id>
    <nct_id>NCT02436668</nct_id>
  </id_info>
  <brief_title>Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)</brief_title>
  <official_title>A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with&#xD;
      nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic&#xD;
      pancreatic adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">April 25, 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
    <description>PFS is defined as the time from the date of randomization until disease progression per RECIST 1.1 criteria assessed by investigator, or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
    <description>OS, is defined as the time from date of randomization until date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine.</measure>
    <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
    <description>This is a measure of percentage of subjects with Treatment Emergent Adverse Events Grade 3 or above collected Up to 30 days after the last participating subject discontinues study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
    <description>ORR is defined as the percentage of subjects who achieve a complete response or partial response, based on investigator assessment according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Response</measure>
    <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
    <description>Subject achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card [MPAC]) or analgesic consumption, or a 20-point or greater improvement in KPS for a period of at least 4 consecutive weeks, without showing any sustained worsening in other parameters.&#xD;
OR Subject was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation (Burris 1997).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbohydrate Antigen 19-9 (CA19-9) Response</measure>
    <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
    <description>The CA19-9 response rate is defined as the percentage of subjects with a decline of 20%, 90%, and other thresholds considered clinically meaningful, from baseline. This is a percentage of patients with &gt; or = 60% reduction from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).</measure>
    <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
    <description>Unit is the month: TUDD1 - the time between random &amp; 1st occurrence of a decrease in QLQ-C30 score ≥10 pts w/o improvement in QoL score of ≥10 points or any further QoL data due to deterioration. The proportion of subjects who met the &quot;responder&quot; criteria prior to subsequent anticancer therapy initiation. Response defined as achievement of a ≥50% reduction in MPAC visual analog scale which measures pain intensity or analgesic consumption, or a ≥20-point improvement from baseline in KPS sustained for a period of ≥ 4 consecutive weeks without showing any sustained worsening from baseline in any of the other parameters OR Subject stable on all parameters (pain and KPS), &amp; showed a marked, sustained weight gain (≥7% increase from baseline maintained for ≥4 weeks) not due to fluid accumulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Venous Thromboembolic Events (VTE)</measure>
    <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
    <description>The VTE rate is defined as percentage of subjects with Venous thromboembolic events (SMQ) per investigator assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>Ibrutinib</arm_group_label>
    <other_name>IMBRUVICA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma.&#xD;
&#xD;
          2. Stage IV disease diagnosed within 6 weeks of randomization&#xD;
&#xD;
          3. Adequate hematologic function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.5 x 109/L&#xD;
&#xD;
               -  Platelet count ≥100 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
          4. Adequate hepatic and renal function defined as:&#xD;
&#xD;
               -  AST and/or ALT ≤5.0 x upper limit of normal (ULN) if liver metastases, or ≤3 x&#xD;
                  ULN without liver metastases&#xD;
&#xD;
               -  Alkaline phosphatase &lt;3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present&#xD;
&#xD;
               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
                  non-hepatic origin, such as hemolysis)&#xD;
&#xD;
               -  Estimated Creatinine Clearance ≥30 mL/min&#xD;
&#xD;
          5. PT/INR &lt;1.5 x ULN and PTT (aPTT) &lt;1.5 x ULN&#xD;
&#xD;
          6. KPS ≥70.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapies: BTK inhibitor, radiotherapy, radiotherapy in the adjuvant setting, or&#xD;
             cytotoxic chemotherapy for primary disease of pancreatic adenocarcinoma.&#xD;
&#xD;
          2. Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma&#xD;
&#xD;
          3. Known brain or leptomeningeal disease (CT or MRI scan of the brain required only in&#xD;
             case of clinical suspicion of central nervous system involvement).&#xD;
&#xD;
          4. Major surgery within 4 weeks of first dose of study drug.&#xD;
&#xD;
          5. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.&#xD;
&#xD;
          6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Cole, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Specialties, PC; Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care</name>
      <address>
        <city>Avondale</city>
        <state>Arizona</state>
        <zip>85323</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Daly City</city>
        <state>California</state>
        <zip>94015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology/Oncology Assoc.</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Memorial Hospital</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital Cancer Research Center</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>64026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates, LTD</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Bird Perkins Cancer Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Physician Group</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berkshire Hematology Oncology Services at Berkshire Medical Center Cancer and Infusion Center</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Health System</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow Regional Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Medicine - Peggy D. Cowdery Patient Care Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State University Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital &amp; Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C. H. U. Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice cedex 02</city>
        <state>Alpes Maritimes</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg cedex</city>
        <state>Bas Rhin</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille cedex 5</city>
        <state>Bouches-du-Rhône</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon cedex</city>
        <state>Côte-d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <state>Doubs</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Saint André - Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche Comté</name>
      <address>
        <city>Doubs</city>
        <state>Montbeliard</state>
        <zip>25209</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris cedex 12</city>
        <state>Paris</state>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers - Hôpital la Milétrie</name>
      <address>
        <city>Poitiers Cedex</city>
        <state>Vienne</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden Wuerttemberg</state>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Haematologie und Onkologie</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen Anhalt</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig AoeR</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Kurfuerstendamm</name>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IEO Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IOV - Istituto Oncologico Veneto IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO l´Hospitalet - Hospital Duran i Reynals</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialist</name>
      <address>
        <city>Barcelona</city>
        <zip>08006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broomfield Hospital</name>
      <address>
        <city>Chelmsford</city>
        <state>Essex</state>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <results_first_submitted>October 31, 2019</results_first_submitted>
  <results_first_submitted_qc>October 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2020</results_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02436668/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02436668/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 75 centers in the United States (US), European Union, and South Korea. The first subject enrolled 08 May 2015 and the last was enrolled on April 19, 2018.</recruitment_details>
      <pre_assignment_details>There was a safety run-in of 6 patients; subsequently, 430 total patients were enrolled. Eligible subjects were required to have a confirmed diagnosis of Stage IV pancreatic adenocarcinoma within 6 weeks of randomization evaluable per RECIST 1.1 criteria with at least 1 measurable metastatic lesion. Key exclusion criteria included any previous cytotoxic chemotherapy for primary disease of pancreatic adenocarcinoma.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo+Gemcitabine+Nab-Paclitaxel</title>
          <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine&#xD;
Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
        </group>
        <group group_id="P2">
          <title>Ibrutinib+Gemcitabine+Nab-paclitaxel</title>
          <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine&#xD;
Ibrutinib was administered orally once daily at a starting dose of 560 mg.&#xD;
Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pbo+n-P/G</title>
          <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine&#xD;
Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.</description>
        </group>
        <group group_id="B2">
          <title>Ibr+n-P/G</title>
          <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine&#xD;
Ibrutinib- orally once daily at a starting dose of 560 mg.&#xD;
Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="213"/>
            <count group_id="B2" value="211"/>
            <count group_id="B3" value="424"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" lower_limit="32" upper_limit="85"/>
                    <measurement group_id="B2" value="64.0" lower_limit="32" upper_limit="82"/>
                    <measurement group_id="B3" value="64.0" lower_limit="32" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="395"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS is defined as the time from the date of randomization until disease progression per RECIST 1.1 criteria assessed by investigator, or death from any cause, whichever occurs first.</description>
        <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+Gemcitabine+Nab-paclitaxel</title>
            <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Ibrutinib was administered orally once daily at a starting dose of 560 mg. Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Gemcitabine+Nab-Paclitaxel</title>
            <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS is defined as the time from the date of randomization until disease progression per RECIST 1.1 criteria assessed by investigator, or death from any cause, whichever occurs first.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32" lower_limit="3.75" upper_limit="5.49"/>
                    <measurement group_id="O2" value="6.01" lower_limit="5.45" upper_limit="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment effect was tested with an stratified log rank test. Hazard ratio is estimated using Cox regression model stratified by the three randomization stratification factors [KPS (70 80 vs. 90-100), liver metastasis (present vs. absent), and age (≤65 vs. &gt;65)] and with treatment as the only covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is from log-rank test stratified by the three randomization stratification factors [KPS (70-80 vs. 90-100), liver metastasis (present vs. absent), and age (≤65 vs. &gt;65)].</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.525</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.241</ci_lower_limit>
            <ci_upper_limit>1.873</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS, is defined as the time from date of randomization until date of death from any cause.</description>
        <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+Gemcitabine+Nab-paclitaxel</title>
            <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Ibrutinib was administered orally once daily at a starting dose of 560 mg. Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Gemcitabine+Nab-Paclitaxel</title>
            <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS, is defined as the time from date of randomization until date of death from any cause.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.69" lower_limit="8.57" upper_limit="10.41"/>
                    <measurement group_id="O2" value="10.78" lower_limit="8.94" upper_limit="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment effect was tested with an stratified log rank test. Hazard ratio is estimated using Cox regression model stratified by the three randomization stratification factors [KPS (70 80 vs. 90-100), liver metastasis (present vs. absent), and age (≤65 vs. &gt;65)] and with treatment as the only covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-value is based on log-rank test stratified by the three randomization stratification factors [KPS (70-80 vs. 90-100), liver metastasis (present vs. absent), and age (≤65 vs. &gt;65)].</non_inferiority_desc>
            <p_value>0.3225</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.109</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.903</ci_lower_limit>
            <ci_upper_limit>1.363</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine.</title>
        <description>This is a measure of percentage of subjects with Treatment Emergent Adverse Events Grade 3 or above collected Up to 30 days after the last participating subject discontinues study drug.</description>
        <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
        <population>The safety population included 420 subjects and was used for the analyses of all safety endpoints and included all subjects in the ITT population who received at least 1 dose of study drug (ibrutinib, placebo, nab-paclitaxel, or gemcitabine). The data sets analyzed are summarized in the following table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Gemcitabine+Nab-Paclitaxel</title>
            <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Ibrutinib+Gemcitabine+Nab-paclitaxel</title>
            <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Ibrutinib was administered orally once daily at a starting dose of 560 mg. Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine.</title>
          <description>This is a measure of percentage of subjects with Treatment Emergent Adverse Events Grade 3 or above collected Up to 30 days after the last participating subject discontinues study drug.</description>
          <population>The safety population included 420 subjects and was used for the analyses of all safety endpoints and included all subjects in the ITT population who received at least 1 dose of study drug (ibrutinib, placebo, nab-paclitaxel, or gemcitabine). The data sets analyzed are summarized in the following table.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any TEAE &gt;= Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with ibrutinib/pbo-related TEAE &gt;=Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7"/>
                    <measurement group_id="O2" value="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>ORR is defined as the percentage of subjects who achieve a complete response or partial response, based on investigator assessment according to RECIST 1.1.</description>
        <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Gemcitabine+Nab-Paclitaxel</title>
            <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Ibrutinib+Gemcitabine+Nab-paclitaxel</title>
            <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Ibrutinib was administered orally once daily at a starting dose of 560 mg. Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>ORR is defined as the percentage of subjects who achieve a complete response or partial response, based on investigator assessment according to RECIST 1.1.</description>
          <units>percentage of Patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" lower_limit="35.5" upper_limit="49.2"/>
                    <measurement group_id="O2" value="29.5" lower_limit="23.3" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For rate ratio, numerator is Ibr+Gem/Abr arm and denominator is Pbo + Gem/Abr arm. P-value for rate ratio is based on Cochran-Mantel-Haenszel (CMH) test adjusted for the three randomization stratification factors. Two-sided 95% confidence interval for rate ratio is based on Mantel-Haenszel method.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.695</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.535</ci_lower_limit>
            <ci_upper_limit>0.903</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Response</title>
        <description>Subject achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card [MPAC]) or analgesic consumption, or a 20-point or greater improvement in KPS for a period of at least 4 consecutive weeks, without showing any sustained worsening in other parameters.&#xD;
OR Subject was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation (Burris 1997).</description>
        <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
        <population>Clinical benefit response rate was not analyzed due to incomplete data for the analgesic use. Data for subjects who &quot;Achieved a &gt;=50% reduction in pain intensity&quot;, &quot;20-point or greater improvement in KPS (&gt;=4 consecutive weeks)&quot;, &quot;Sustained weight gain (&gt;=7% increase maintained for &gt;=4 weeks) not due to fluid accumulation&quot;are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Gemcitabine+Nab-Paclitaxel</title>
            <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Ibrutinib+Gemcitabine+Nab-paclitaxel</title>
            <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Ibrutinib was administered orally once daily at a starting dose of 560 mg. Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.&#xD;
I</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Response</title>
          <description>Subject achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card [MPAC]) or analgesic consumption, or a 20-point or greater improvement in KPS for a period of at least 4 consecutive weeks, without showing any sustained worsening in other parameters.&#xD;
OR Subject was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation (Burris 1997).</description>
          <population>Clinical benefit response rate was not analyzed due to incomplete data for the analgesic use. Data for subjects who &quot;Achieved a &gt;=50% reduction in pain intensity&quot;, &quot;20-point or greater improvement in KPS (&gt;=4 consecutive weeks)&quot;, &quot;Sustained weight gain (&gt;=7% increase maintained for &gt;=4 weeks) not due to fluid accumulation&quot;are reported.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieved a &gt;=50% reduction in pain intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20-pt improvement in KPS (&gt;=4 consecutive weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained weight gain (&gt;=7% maintained &gt;4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carbohydrate Antigen 19-9 (CA19-9) Response</title>
        <description>The CA19-9 response rate is defined as the percentage of subjects with a decline of 20%, 90%, and other thresholds considered clinically meaningful, from baseline. This is a percentage of patients with &gt; or = 60% reduction from baseline.</description>
        <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Gemcitabine+Nab-Paclitaxel</title>
            <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Ibrutinib+Gemcitabine+Nab-paclitaxel</title>
            <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Ibrutinib was administered orally once daily at a starting dose of 560 mg. Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Carbohydrate Antigen 19-9 (CA19-9) Response</title>
          <description>The CA19-9 response rate is defined as the percentage of subjects with a decline of 20%, 90%, and other thresholds considered clinically meaningful, from baseline. This is a percentage of patients with &gt; or = 60% reduction from baseline.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" lower_limit="56.0" upper_limit="69.4"/>
                    <measurement group_id="O2" value="53.6" lower_limit="46.6" upper_limit="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For rate ratio, numerator is Ibr+Gem/Abr arm and denominator is Pbo+Gem/Abr arm. P-value for rate ratio is based on Cochran-Mantel-Haenszel (CMH) test adjusted for the three randomization stratification factors. Two-sided 95% confidence interval for rate ratio is based on Mantel-Haenszel method.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0488</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.850</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.722</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>This 0.85 (0.722 to 1.0) with CI is referring to risk ratio not proportional/percentage of patients.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).</title>
        <description>Unit is the month: TUDD1 - the time between random &amp; 1st occurrence of a decrease in QLQ-C30 score ≥10 pts w/o improvement in QoL score of ≥10 points or any further QoL data due to deterioration. The proportion of subjects who met the &quot;responder&quot; criteria prior to subsequent anticancer therapy initiation. Response defined as achievement of a ≥50% reduction in MPAC visual analog scale which measures pain intensity or analgesic consumption, or a ≥20-point improvement from baseline in KPS sustained for a period of ≥ 4 consecutive weeks without showing any sustained worsening from baseline in any of the other parameters OR Subject stable on all parameters (pain and KPS), &amp; showed a marked, sustained weight gain (≥7% increase from baseline maintained for ≥4 weeks) not due to fluid accumulation.</description>
        <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Gemcitabine+Nab-Paclitaxel</title>
            <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Ibrutinib+Gemcitabine+Nab-paclitaxel</title>
            <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Ibrutinib was administered orally once daily at a starting dose of 560 mg. Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).</title>
          <description>Unit is the month: TUDD1 - the time between random &amp; 1st occurrence of a decrease in QLQ-C30 score ≥10 pts w/o improvement in QoL score of ≥10 points or any further QoL data due to deterioration. The proportion of subjects who met the &quot;responder&quot; criteria prior to subsequent anticancer therapy initiation. Response defined as achievement of a ≥50% reduction in MPAC visual analog scale which measures pain intensity or analgesic consumption, or a ≥20-point improvement from baseline in KPS sustained for a period of ≥ 4 consecutive weeks without showing any sustained worsening from baseline in any of the other parameters OR Subject stable on all parameters (pain and KPS), &amp; showed a marked, sustained weight gain (≥7% increase from baseline maintained for ≥4 weeks) not due to fluid accumulation.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.14" lower_limit="4.86" upper_limit="8.21"/>
                    <measurement group_id="O2" value="4.21" lower_limit="2.86" upper_limit="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>[1] Hazard ratio is based on a Cox proportional hazards model stratified by the three randomization stratification factors for time until definitive deterioration (TUDD1), a hazard ratio &lt; 1 favors Ibr + Gem/Abr. TUDD1 is defined as the time interval between randomization and the first occurrence of a decrease in score by &gt;= 10 points without any further improvement in score by &gt;= 10 points or any further available QoL data due to dropout after deterioration.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0782</p_value>
            <p_value_desc>P-value is from log-rank test stratified by the three randomization stratification factors.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.265</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.975</ci_lower_limit>
            <ci_upper_limit>1.642</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Venous Thromboembolic Events (VTE)</title>
        <description>The VTE rate is defined as percentage of subjects with Venous thromboembolic events (SMQ) per investigator assessment.</description>
        <time_frame>Results at an overall median follow-up of 24.87 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Gemcitabine+Nab-Paclitaxel</title>
            <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Ibrutinib+Gemcitabine+Nab-paclitaxel</title>
            <description>Ibrutinib daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine Ibrutinib was administered orally once daily at a starting dose of 560 mg. Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Venous Thromboembolic Events (VTE)</title>
          <description>The VTE rate is defined as percentage of subjects with Venous thromboembolic events (SMQ) per investigator assessment.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="7.0" upper_limit="15.8"/>
                    <measurement group_id="O2" value="8.1" lower_limit="4.8" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For rate of VTEs, denominator is number of subjects in the Intent-to-Treat population and numerator is number of Intent-to-Treat subjects with at least one VTE observed any time on study. Confidence interval for rate of VTEs is based on Clopper-Pearson method.&#xD;
[1] P value is based on Chi-square test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3343</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to 30 days after the last dose of study drug</time_frame>
      <desc>There were 4 patient that was randomized but off study without any treatment. This patient had received baseline assessments and included in all efficacy analysis but was excluded from safety population, i.e. not at risk for AE assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Plus Nab-paclitaxel and Gemcitabine)</title>
          <description>Placebo daily in combination with:&#xD;
Nab-paclitaxel and gemcitabine&#xD;
Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
        </group>
        <group group_id="E2">
          <title>Ibrutinib (Plus Nab-paclitaxel and Gemcitabine)</title>
          <description>Ibrutinib 560 mg (4 x 140 mg capsules) (or placebo) was administered orally once daily beginning on Day 1 of Cycle 1 of the treatment phase, with the first dose of ibrutinib given no more than 72 hours after randomization&#xD;
Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="212"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Haemorrhagic diathesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="212"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="212"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Small intestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="212"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="212"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Vascular device infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Enzyme abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="208" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="309" subjects_affected="95" subjects_at_risk="212"/>
                <counts group_id="E2" events="289" subjects_affected="90" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="208" subjects_affected="55" subjects_at_risk="212"/>
                <counts group_id="E2" events="221" subjects_affected="75" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="328" subjects_affected="84" subjects_at_risk="212"/>
                <counts group_id="E2" events="139" subjects_affected="68" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="61" subjects_affected="18" subjects_at_risk="212"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="240" subjects_affected="109" subjects_at_risk="212"/>
                <counts group_id="E2" events="357" subjects_affected="147" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="242" subjects_affected="107" subjects_at_risk="212"/>
                <counts group_id="E2" events="228" subjects_affected="116" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="184" subjects_affected="86" subjects_at_risk="212"/>
                <counts group_id="E2" events="169" subjects_affected="85" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="96" subjects_affected="78" subjects_at_risk="212"/>
                <counts group_id="E2" events="91" subjects_affected="68" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="99" subjects_affected="67" subjects_at_risk="212"/>
                <counts group_id="E2" events="94" subjects_affected="63" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="40" subjects_affected="27" subjects_at_risk="212"/>
                <counts group_id="E2" events="64" subjects_affected="38" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="21" subjects_at_risk="212"/>
                <counts group_id="E2" events="50" subjects_affected="36" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="212"/>
                <counts group_id="E2" events="38" subjects_affected="34" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="35" subjects_affected="25" subjects_at_risk="212"/>
                <counts group_id="E2" events="30" subjects_affected="21" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="212"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="283" subjects_affected="93" subjects_at_risk="212"/>
                <counts group_id="E2" events="311" subjects_affected="100" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="181" subjects_affected="82" subjects_at_risk="212"/>
                <counts group_id="E2" events="150" subjects_affected="85" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="170" subjects_affected="65" subjects_at_risk="212"/>
                <counts group_id="E2" events="149" subjects_affected="78" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="143" subjects_affected="77" subjects_at_risk="212"/>
                <counts group_id="E2" events="97" subjects_affected="60" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="29" subjects_affected="19" subjects_at_risk="212"/>
                <counts group_id="E2" events="36" subjects_affected="24" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="16" subjects_at_risk="212"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="33" subjects_affected="21" subjects_at_risk="212"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="61" subjects_affected="17" subjects_at_risk="212"/>
                <counts group_id="E2" events="26" subjects_affected="13" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="42" subjects_affected="25" subjects_at_risk="212"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="48" subjects_affected="19" subjects_at_risk="212"/>
                <counts group_id="E2" events="19" subjects_affected="11" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="34" subjects_affected="18" subjects_at_risk="212"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="129" subjects_affected="76" subjects_at_risk="212"/>
                <counts group_id="E2" events="135" subjects_affected="85" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="212"/>
                <counts group_id="E2" events="37" subjects_affected="25" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="16" subjects_at_risk="212"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="212"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="58" subjects_affected="35" subjects_at_risk="212"/>
                <counts group_id="E2" events="36" subjects_affected="28" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="38" subjects_affected="25" subjects_at_risk="212"/>
                <counts group_id="E2" events="31" subjects_affected="25" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="212"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="212"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="212"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="212"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="153" subjects_affected="63" subjects_at_risk="212"/>
                <counts group_id="E2" events="171" subjects_affected="69" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="20" subjects_at_risk="212"/>
                <counts group_id="E2" events="79" subjects_affected="27" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="212"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="212"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="212"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="28" subjects_affected="14" subjects_at_risk="212"/>
                <counts group_id="E2" events="33" subjects_affected="15" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="47" subjects_affected="18" subjects_at_risk="212"/>
                <counts group_id="E2" events="40" subjects_affected="14" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="23" subjects_affected="11" subjects_at_risk="212"/>
                <counts group_id="E2" events="30" subjects_affected="13" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="212"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="212"/>
                <counts group_id="E2" events="41" subjects_affected="36" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="64" subjects_affected="43" subjects_at_risk="212"/>
                <counts group_id="E2" events="34" subjects_affected="25" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="47" subjects_affected="42" subjects_at_risk="212"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="212"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="212"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="119" subjects_affected="87" subjects_at_risk="212"/>
                <counts group_id="E2" events="130" subjects_affected="90" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="42" subjects_affected="28" subjects_at_risk="212"/>
                <counts group_id="E2" events="28" subjects_affected="23" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="36" subjects_affected="25" subjects_at_risk="212"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="212"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="34" subjects_affected="13" subjects_at_risk="212"/>
                <counts group_id="E2" events="33" subjects_affected="11" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution/Investigator will not publish without Sponsor prior review and approval&#xD;
Institution/Investigator will not publish until the earlier of (i) results of study are submitted for publication (ii) notification that submission of the multicenter results are no longer planned (iii) 18 months after study termination.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George Cole</name_or_title>
      <organization>Pharmacyclics, An AbbVie Company</organization>
      <phone>(408) 990-7340</phone>
      <email>gcole@pcyc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

